The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic
Open accessAbstract
Importance: The COVID-19 pandemic led to sharp declines in cancer screening. However, the total deficit in screening in the US associated with the pandemic and the differential impact on individuals in different geographic regions and by socioeconomic status (SES) index have yet to be fully characterized. Objectives: To quantify the screening rates for breast, colorectal, and prostate cancers associated with the COVID-19 pandemic in different geographic regions and for individuals in different SES index quartiles and estimate the overall cancer screening deficit in 2020 across the US population. Design, Setting, and Participants: This retrospective cohort study uses the HealthCore Integrated Research Database, which comprises single-payer administrative claims data and enrollment information covering approximately 60 million people in Medicare Advantage and commercial health plans from across geographically diverse regions of the US. Participants were individuals in the database in January through July of 2018, 2019, and 2020 without diagnosis of the cancer of interest prior to the analytic index month. Exposures: Analytic index month and year. Main Outcomes and Measures: Receipt of breast, colorectal, or prostate cancer screening. Results: Screening for all 3 cancers declined sharply in March through May of 2020 compared with 2019, with the sharpest decline in April (breast, -90.8%; colorectal, -79.3%; prostate, -63.4%) and near complete recovery of monthly screening rates by July for breast and prostate cancers. The absolute deficit across the US population in screening associated with the COVID-19 pandemic was estimated to be 3.9 million (breast), 3.8 million (colorectal), and 1.6 million (prostate). Geographic differences were observed: the Northeast experienced the sharpest declines in screening, while the West had a slower recovery compared with the Midwest and South. For example, percentage change in breast cancer screening rate (2020 vs 2019) for the month of April ranged from -87.3% (95% CI, -87.9% to -86.7%) in the West to -94.5% (95% CI, -94.9% to -94.1%) in the Northeast (decline). For the month of July, it ranged from -0.3% (95% CI, -2.1% to 1.5%) in the Midwest to -10.6% (-12.6% to -8.4%) in the West (recovery). By SES, the largest screening decline was observed in individuals in the highest SES index quartile, leading to a narrowing in the disparity in cancer screening by SES in 2020. For example, prostate cancer screening rates per 100 000 enrollees for individuals in the lowest and highest SES index quartiles, respectively, were 3525 (95% CI, 3444 to 3607) and 4329 (95% CI, 4271 to 4386) in April 2019 compared with 1535 (95% CI, 1480 to 1589) and 1338 (95% CI, 1306 to 1370) in April 2020. Multivariable analysis showed that telehealth use was associated with higher cancer screening. Conclusions and Relevance: Public health efforts are needed to address the large cancer screening deficit associated with the COVID-19 pandemic, including increased use of screening modalities that do not require a procedure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of a combined comorbidity index
Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(94)90129-5 · Cited by 6,587
Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D. C., Curry, S. J., Davidson, K. W., Epling, J. W., García, F. A. R., Gillman, M. W., Harper, D. M., Kemper, A. R., et al. (2016) · JAMA · doi:10.1001/jama.2016.5989 · Cited by 2,509
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Siu, A. L., & on behalf of the U.S. Preventive Services Task Force (2016) · Annals of Internal Medicine · doi:10.7326/m15-2886 · Cited by 2,094
Maringe, C., Spicer, J., Morris, M., Purushotham, A., Nolte, E., Sullivan, R., Rachet, B., & Aggarwal, A. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30388-0 · Cited by 1,807
Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-10-200911170-00008 · Cited by 1,686
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Bibbins-Domingo, K., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Ebell, M., Epling, J. W., et al. (2018) · JAMA · doi:10.1001/jama.2018.3710 · Cited by 1,436
Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram‐Baptiste, D., Saslow, D., & Wender, R. C. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21557 · Cited by 701
Whaley, C. M., Pera, M. F., Cantor, J., Chang, J., Velasco, J., Hagg, H. K., Sood, N., & Bravata, D. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.24984 · Cited by 426
Sharpless, N. E. (2020) · Science · doi:10.1126/science.abd3377 · Cited by 408
Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic
Bakouny, Z., Paciotti, M., Schmidt, A. L., Lipsitz, S. R., Choueiri, T. K., & Trinh, Q.-D. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.7600 · Cited by 268
Cited by
Racial and Ethnic Disparities in Cancer Care During the COVID-19 Pandemic
Patel, M. I., Ferguson, J. M., Castro, E., Pereira-Estremera, C. D., Armaiz-Peña, G. N., Duron, Y., Hlubocky, F., Infantado, A., Nuqui, B., Julian, D., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.22009 · Cited by 53
Johansson, A. L. V., Larønningen, S., Skovlund, C. W., Kristiansen, M. F., Mørch, L. S., Friis, S., Johannesen, T. B., Myklebust, T. Å., Skog, A., Pettersson, D., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34029 · Cited by 38
Gaudio, E., Ammar, N., Gunturkun, F., Akkus, C., Brakefield, W., Wakefield, D. V., Pisu, M., Davis, R., Shaban-Nejad, A., & Schwartz, D. L. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.09.073 · Cited by 11
A “Sludge Audit” for Health System Colorectal Cancer Screening Services
(2023) · The American Journal of Managed Care · doi:10.37765/ajmc.2023.89402 · Cited by 10
Metadata
- Authors
- Chen, R. C., Haynes, K., Du, S., Barron, J., & Katz, A. J.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2021-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 878
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W3157801830
- Cited by
- 315
- References
- 14
- FWCI
- 21.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. https://app.cochat.ai/papers/10.1001/jamaoncol.2021.0884
- The paper
- Chen, R. C., Haynes, K., Du, S., Barron, J., & Katz, A. J. (2021). Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.0884
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.